ArticleMolecular biology reports2026
Optimization of a hybridization-based target enrichment protocol for precision oncology.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multidisciplinary and Personalized Molecular Diagnosis to Solving Sudden Death During Sport.Molecular diagnosis & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNext-generation sequencing has become an essential tool in precision oncology, enabling comprehensive detection of clinically relevant genomic alterations. This study aimed to optimize a hybridization-based enrichment protocol for formalin-fixed paraffin-embedded (FFPE)-derived DNA and to evaluate its performance relative to commercial hybridization- and amplification-based kits. METHODS AND
resultsHybridization conditions, including temperature, duration, buffer composition, and the number of capture rounds, were systematically varied to maximize enrichment efficiency and coverage uniformity. Libraries were sequenced using Illumina platforms and analyzed for enrichment metrics, duplicate fraction, target depth, and variant detection. Comparative analyses were performed against commercial hybridization-based and amplification-based kits, as well as a whole-exome capture panel. Two rounds of short hybridization provided the highest enrichment efficiency while maintaining complete target coverage. The optimized protocol demonstrated approximately sixfold higher enrichment than the hybridization-based analogue, ensuring adequate coverage despite increased duplicate rates. Scalability testing showed performance comparable to a commercial whole-exome kit, with maintained enrichment efficiency and target depth across large panels.
conclusionsThe optimized hybridization-based enrichment protocol provides superior target coverage, high variant recall, and flexibility for scaling from small panels to whole-exome sequencing, supporting its suitability for precision oncology applications in challenging FFPE samples.
Indexed as
Identifiers
42234253What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.